Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Chloroprocaine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A known ✓ | P35498 | 5/20 | 0.66 |
| ▸ | SCN2A known ✓ | Q99250 | 5/20 | 0.66 |
| ▸ | SCN3A known ✓ | Q9NY46 | 5/20 | 0.66 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.97 |
| ▸ | HTR3A | P46098 | 3/20 | 0.97 |
| ▸ | MAOA | P21397 | 3/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.97 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.97 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.97 |
| ▸ | HTR2C | P28335 | 1/20 | 0.97 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.66 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 4/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chloroprocaine SCHEMBL24096 | 1.00 | HRH3 (0.97) | HRH3HTR3AMAOAKCNH2CHRM2 | |
| Chloroprocaine SCHEMBL6676 | 0.99 | HRH3 (1.00) | HRH3HTR3AMAOAKCNH2CHRM2 | |
| Chloroprocaine SCHEMBL29354179 | 0.99 | HRH3 (1.00) | HRH3HTR3AMAOAKCNH2CHRM2 | |
| Chloroprocaine SCHEMBL21612249 | 0.97 | HRH3 (0.97) | HRH3HTR3AMAOAKCNH2CHRM2 | |
| Chloroprocaine SCHEMBL28104711 | 0.93 | HRH3 (0.88) | HRH3HTR3AMAOAKCNH2CHRM2 | |
| Chloroprocaine SCHEMBL6272449 | 0.92 | HRH3 (0.86) | HRH3HTR3AMAOAKCNH2CHRM2 | |
| SCHEMBL13440006 | 0.90 | HRH3 (0.84) | HRH3HTR3AMAOAKCNH2CHRM2 | |
| Chloroprocaine SCHEMBL2471312 | 0.90 | MAOA (0.82) | HRH3HTR3AMAOAKCNH2CHRM2 | |
| Chloroprocaine SCHEMBL3808985 | 0.89 | HRH3 (0.80) | HRH3HTR3AMAOAKCNH2CHRM2 | |
| SCHEMBL13440004 | 0.87 | HTR3A (0.79) | HRH3HTR3AMAOAKCNH2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| CN-115029392-A | Method for preparing lactic acid by fermenting kitchen waste with rhizopus oryzae | 苏州星寰生物科技有限公司 | 2022-09-09 | — | — | CN | claimed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12465564-B2 | Oral and nasal compositions and methods of treatment | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250339367-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-12403090-B2 | Oral film compositions and dosage forms having precise active dissolution profiles | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250255780-A1 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-08-14 | — | — | US | disclosed |
| CN-120121749-A | Method for detecting 18 local anesthetics in cosmetics | 苏州市药品检验检测研究中心（苏州市药品不良反应监测中心） | 2025-06-10 | — | — | CN | disclosed |
| US-12310922-B2 | System and method for making personalized individual unit doses containing pharmaceutical actives | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-12290597-B2 | Oral film compositions and dosage forms having precise active dissolution profiles | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| EP-3970723-A1 | AMINOINDANE COMPOUNDS FOR USE IN TREATING UROLOGICAL PAIN | Asana BioSciences, LLC (US) | 2022-03-23 | — | — | EP | disclosed |
| WO-2022049149-A1 | CHEWABLE FORMULATIONS | ELANCO TIERGESUNDHEIT AG (CH) | 2022-03-10 | — | — | WO | disclosed |
| US-9504666-B2 | Chloroprocaine-based pharmaceutical composition for repeated intrathecal administration | SINTETICA S.A. (CH) | 2016-11-29 | — | — | US | disclosed |
| US-20150320716-A1 | CHLOROPROCAINE-BASED PHARMACEUTICAL COMPOSITION FOR REPEATED INTRATHECAL ADMINISTRATION | SINTETICA S.A. (CH) | 2015-11-12 | — | — | US | disclosed |
| US-8969412-B2 | Use for a composition comprising chloroprocaine HCL, a new composition comprising chloroprocaine HCL and a method for its manufacture | SINTETICA S.A. (CH) | 2015-03-03 | — | — | US | disclosed |
| EP-1931304-B1 | NEW USE FOR A COMPOSITION COMPRISING CHLOROPROCAINE HCL, A NEW COMPOSITION COMPRISING CHLOROPROCAINE HCL AND A METHOD FOR ITS MANUFACTURE | SINT SA (CH) | 2013-10-16 | — | — | EP | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20080306149-A1 | Use for a Composition Comprising Chloroprocaine Hcl, a New Composition Comprising Chloroprocaine Hcl and a Method for Its Manufacture | SINTETICA S.A. (CH) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | SCN1A 20/4885SCN2A 24/4885SCN3A 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.